Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport

S Ménard, C Candalh, J C Bambou, K Terpend, N Cerf-Bensussan, M Heyman


Background: Probiotic bacteria have a beneficial effect on intestinal inflammation. In this study, we have examined the effect of lactic acid and commensal Gram positive (+) bacteria conditioned media (CM) on tumour necrosis factor α (TNF-α) release and the mechanisms involved.

Methods: Lipopolysaccharide (LPS) induced TNF-α secretion by peripheral blood mononuclear cells or the THP-1 cell line was monitored in the presence or absence of bacteria CM obtained from two probiotic strains, *Bifidobacterium breve* (Bb) and *Streptococcus thermophilus* (St), and three commensal bacterial strains (*Bifidobacterium bifidum*, *Ruminococcus gravis*, and unidentified *Streptococcus*). Bb and St bacteria CM were allowed to cross filter grown intestinal epithelial cell monolayers (HT29-19A) to assess intestinal transport of active bacterial products. These products were characterised and their effect on LPS binding to THP-1 cells and nuclear factor κB (NFκB) activation assessed.

Results: Dose dependent inhibition of LPS induced TNF-α secretion was noted for both probiotic bacteria CM (64% and 71% inhibition for Bb and St, respectively) and to a lesser extent commensal bacteria CM (21–32% inhibition). Active products from Bb and St were resistant to digestive enzymes and had a molecular mass <3000 Da. Their inhibitory effect was preserved after transepithelial transport across intestinal cell monolayers, mainly in inflammatory conditions. LPS-FITC binding to THP-1 cells and NFκB activation were significantly inhibited by Bb and St CM.

Conclusion: *B breve* and *S thermophilus* release metabolites exerting an anti-TNF-α effect capable of crossing the intestinal barrier. Commensal bacteria also display a TNF-α inhibitory capacity but to a lesser extent. These results underline the beneficial effect of commensal bacteria in intestinal homeostasis and may explain the role of some probiotic bacteria in alleviating digestive inflammation.

Various beneficial effects to human health have been attributed to probiotic bacteria, mainly at the intestinal level. There is convergent evidence suggesting that probiotics may have anti-inflammatory properties. Allergic inflammation can benefit from the use of probiotics as an adjunct to conventional treatment. Indeed, it was reported that cow’s milk allergic infants, treated with extensively hydrolysed milk formula supplemented with *Lactobacillus rhamnosus* GG, had a better clinical score and less tumour necrosis factor α (TNF-α) in their faeces than infants treated with the hydrolysed formula only. Gastric inflammation associated with *Helicobacter pylori* infection was improved by supplementing conventional treatment with probiotic bacteria. Interestingly, different lactobacilli, bifidobacteria, or probiotic mixtures (VSL#3) have been shown to alleviate digestive diseases in experimental animals and in inflammatory bowel diseases in humans. In neonatal rats suffering from stress induced necrotising enterocolitis, preliminary administration of *Bifidobacterium infantis* was protective towards enterocolitis development. Recently, it was also shown that *Lactobacillus rhamnosus* GG conditioned media decreased TNF-α production by macrophages in vitro by a contact independent mechanism. However, clear beneficial effects still remain controversial. Other studies have stressed the specificity of bacterial strains in inducing anti- or proinflammatory cytokines. Indeed, some lactic acid bacteria, or their secretion products, orally administered in mice (*Lactobacillus reuteri* or *Lactobacillus brevis*), had a stimulatory effect on secretion of proinflammatory cytokines such as interleukin (IL)-1β and TNF-α.

Probiotics are generally administered via the oral route and the intestinal epithelial barrier restricts their interaction with the local immune system. The present study was aimed at characterising the anti-inflammatory (anti-TNF-α) effect of the metabolites produced by two lactic acid bacteria (Bifidobacterium breve and *Streptococcus thermophilus*) compared with three commensal bacteria strains. Lactic acid bacteria metabolites were characterised and possible mechanisms for their anti-inflammatory properties were studied, as well as their capacity to cross the intestinal barrier under normal or inflammatory conditions.

METHODS

Preparation of bacteria conditioned media

Two lactic acid bacterial strains, *Bifidobacterium breve* (strain BbC50) and *Streptococcus thermophilus* (strain St065), and three bacterial strains isolated from the dominant Gram positive human microflora were used. The commensal bacterial strains provided by G Cortiher (INRA, Jouy en Josas, France) comprised Bifidobacterium bifidum strain B536, originally isolated from the faecal flora of a healthy breast fed infant, *Ruminococcus gravis* (GRE1), isolated from the predominant faecal flora of a healthy adult, and a non-identified streptococcus strain isolated from the faecal flora of a one month old infant (named here neonatal streptococcus). All bacterial strains were first cultured on brain-heart medium (bifidobacteria and ruminococcus) or lactose enriched M20 medium (streptococcus). Bacteria were then

Abbreviations: FCS, fetal calf serum; IFN, interferon; IL, interleukin; LBP, LPS binding protein; LPS, lipopolysaccharide; LTA, lipoteichoic acid; NFκB, nuclear factor κB; PBMC, peripheral blood mononuclear cells; SAB, human serum AB; St CM, Streptococcus thermophilus conditioned media; TGfβ, transforming growth factor β; TNF-α, tumour necrosis factor α; TLR, toll-like receptor; IEC, intestinal epithelial cells
collected by centrifugation and cultured over 48 hours in RPMI medium containing 20% fetal calf serum (FCS) and supplemented with 3% inulin (bifidobacteria and ruminococcus) or 3% d-glucose (streptococcus). Bacteria conditioned media (CM) were ultracentrifuged (100 000 g, one hour, 4°C), filtered on 0.22 µm membranes, and frozen (−80°C) until use. Bacteria CM corresponded to 5 × 10^6 and 8 × 10^5 CFU/ml for S thermophilus and B breve, and to 2 × 10^6, 1.5 × 10^5, and 3.3 × 10^5 CFU/ml for R gnavus, B bifidum, and the neonatal streptococcus, respectively.

In experiments comparing the anti-TNF-α effect of probiotic or commensal bacteria CM, dilutions were performed in RPMI/FCS to obtain the same final concentration corresponding to 2.5 × 10^6 CFU/ml. Commensal bacteria CM were also tested at high concentrations (that is, half diluted).

In some experiments, bacteria CM were treated with pepsin and trypsin (0.15 mg/ml) to hydrolyse proteins. To characterise the size of active bacterial products, we submitted bacteria CM to ultrafiltration through Centricon YM-3 or YM-10 membranes that retain molecules larger than 3000 or 10 000 Da, respectively. Retained and filtrated fractions were adjusted to the initial volume and frozen until use.

**Immune cell culture and experimental protocols**

Peripheral blood mononuclear cells (PBMC) of healthy patients were cultured in RPMI 1640 supplemented with 10% human serum AB (SAB), 10 mM HEPES, 1 mM sodium pyruvate, 0.05 mM β-mercapto-ethanol, and 1% penicillin-streptomycin. In some cases, the THP-1 pro-monocytic cell line (ATCC No TIB-202) was cultured in the same culture media containing FCS. PBMC or THP-1 cells were seeded on 24 well (Falcon) plates at 5 × 10^5 cells/well. PBMC were allowed to adhere for one hour and were then stimulated with 1–1000 ng/ml lipopolysaccharide (LPS, ref L2654; Sigma, La verpillière, France) for four hours in the presence or absence of dilutions of native or treated (as described above) bacteria CM. After centrifugation, supernatants were collected and assayed for TNF-α. In some cases, IL-10 secretion was also tested in the presence of bacteria CM and LPS. The optimal LPS concentration shown to activate maximal TNF-α secretion was 10 ng/ml (data not shown). The viability of PBMC in the presence of bacteria CM was tested by propidium iodide incorporation using flow cytometry (BDLSR and CELLquest software; Becton Dickinson, Le Pont de Claix, France). In some cases, PBMC were stimulated with lipoteichoic acid (LTA 100 ng/ml; Sigma) for six hours in the presence or absence of bacteria CM.

TNF-α or IL-10 released by PBMC or THP-1 cells was assayed using commercial enzyme linked immunosorbent assays (ELISA kits; Duoset R&D Systems, Lille, France).

**Analysis of LPS binding to THP-1 pro-monocytes in the presence of bacteria conditioned media by flow cytometry**

LPS has to bind to LPS binding protein (LBP) before LPS-LBP complexes can recognise the CD14 receptor. It can also bind to the toll-like receptor 4 (TLR4). In order to test whether lactic acid bacteria CM may interact with the binding of LPS to monocytes, we measured binding of LPS-FITC (Escherichia coli 055:B5; Sigma), used as a fluorescent marker, by flow cytometry. THP-1 cells were incubated for 48 hours at 2 × 10^6 cell/ml in the presence of vitamin D3 (12 ng/ml) in order to upregulate CD14 receptor expression.

Cells were preincubated for 30 minutes at 4°C with the optimal amount of bacteria CM and further incubated at 4°C for one hour in RPMI containing 10% SAB as a source of LBP, and 2 µg/ml LPS-FITC. In some cases, bovine serum albumin 0.2% was used instead of SAB as a negative control to assess CD14 independent LPS binding.

**Nuclear translocation of NFκB**

Nuclear factor κB (NFκB) activation is characterised by its nuclear translocation. This translocation was demonstrated on nuclear extracts by an electrophoretic migration shift assay.

THP-1 cells (10 × 10^6 cells/ml in RPMI/FCS 1%) were stimulated with 10 ng/ml LPS for 30 minutes in the presence or absence of half diluted CM filtrated fractions <3 kDa, and nuclear and cytoplasmic extracts were prepared as previously described.

Nuclear extracts (5 µg) were placed in binding buffer (10 mM HEPES, pH 7.8, 100 mM NaCl, 1 mM EDTA, and 10% glycerol) containing 1 μg poly(dI-dC)- and 0.5 ng of 32P-labeled DNA probe corresponding to the κB site (5'-GTGGAGGACTTTCCAGG-3'; Promega, Charbonnières, France). Following incubation at room temperature for 30 minutes, samples were run on a 5% polyacrylamide gel in Tris-borate-EDTA buffer. The gel was dried, exposed to a PhosphorImager screen (Molecular Dynamics, Sunnyvale, California, USA), and the ImageQuant software (Molecular Dynamics) was used to perform densitometric analysis.

**Intestinal transport of active bacterial metabolites across the filter grown epithelial cell line HT29-19A under control and inflammatory conditions**

To analyse whether active bacterial metabolites can cross the intestinal barrier, we used filter grown intestinal cell monolayers. HT29-19A cells were seeded on microporous filters (Falcon) at a concentration of 0.8 × 10^6 cells/cm² in Dulbecco’s modified Eagle’s medium supplemented with 10% FCS and 1% gentamicin. Three weeks later, this resulted in a tight polarised monolayer displaying a transepithelial...
Probiotics and inflammation

**Figure 2** Effect of *Streptococcus thermophilus* (St) and *Bifidobacterium breve* (Bb) conditioned media (CM) on basal and lipopolysaccharide (LPS) induced tumour necrosis factor α (TNF-α) secretion by peripheral blood mononuclear cells (PBMC) (A) and the pro-monocytic cell line THP-1 (B). Dose dependent inhibition of TNF-α secretion was observed in the presence of the conditioned media obtained from both bacterial strains. **Statistically significant difference from LPS induced TNF-α secretion (p<0.0001); n = 8 (THP-1 experiments); n = 9–18 (PBMC experiments).**

Electrical resistance of ~150 Ω×cm². Cells were treated (inflammatory conditions) or not (controls) with 100 U/ml interferon (IFN)-α and 10 ng/ml TNF-α placed in basolateral compartments, and incubated for 48 hours. After two extensive washes with RPMI, bacteria CM (or RPMI as control) were added to the apical compartments. After 24 hours, media in the basolateral compartments were collected and tested for their capacity to inhibit LPS induced TNF-α secretion by PBMC, as described above. Electrical resistances of the intestinal cell monolayers were measured at the end of the experiment (that is, after basolateral treatment with IFN-γ and TNF-α) followed by 24 hour apical incubation with bacteria CM or RPMI. Epithelial cells secrete transforming growth factor β (TGF-β), an anti-inflammatory cytokine known to inhibit TNF-α secretion. As this would mask the anti-inflammatory capacity of bacteria CM, the basolateral compartments were coated overnight with an anti-TGF-β antibody (MAB240; R&D) at a concentration of 2 μg/ml before adding bacteria CM to the apical compartment.

**Statistical analysis**

Statistical analysis was performed using the SAS package. Results are expressed as mean (SD) and comparisons of different parameters among the groups were performed using analysis of variance and non-parametric tests (Wilcoxon). Differences were considered significant for values of *p*<0.05.

**RESULTS**

**Effect of lactic acid bacteria and commensal bacteria CM on TNF-α secretion by LPS stimulated PBMC**

Figure 1 indicates that both lactic acid bacteria and commensal bacteria CM used at a final concentration corresponding to 2.5×10⁸ CFU/ml exerted an inhibitory effect on LPS induced TNF-α secretion. This inhibitory effect was significantly higher with lactic acid bacteria CM (43% and 71% inhibition for *B. breve* and *S. thermophilus* CM, respectively) than with commensal bacteria CM (21%, 32%, and 22% for *R. gravis*, *B. bifidum*, and neonatal streptococcus, respectively; *p*<0.04).

We also tested the inhibitory effect of commensal bacteria CM at their highest concentrations (that is, 0.65×10⁶ to 1.65×10⁶ CFU/ml) and found an even more pronounced inhibition, reaching 36%, 77%, and 96% for *R. gravis*, *B. bifidum*, and neonatal streptococcus CM, respectively. Such high concentrations could not be explored with lactic acid bacteria CM as under identical culture conditions their growth was limited to 5 and 8×10⁵ CFU/ml, respectively.

**Figure 3** Effect of *Streptococcus thermophilus* (St) and *Bifidobacterium breve* (Bb) conditioned media (CM) on lipoteichoic acid (LTA) induced tumour necrosis factor α (TNF-α) secretion by peripheral blood mononuclear cells. Inhibition of TNF-α secretion was observed in the presence of Bb-CM (3/4 dilution) and St-CM (1/2 dilution). **Significantly different from LTA induced TNF-α secretion (p<0.0001); n = 4–7 separate experiments.**

**Figure 4** Effect of *Bifidobacterium breve* (Bb) and *Streptococcus thermophilus* (St) conditioned media (CM) on interleukin 10 (IL-10) secretion by peripheral blood mononuclear cells. CM were used at their maximal concentration (1/2 and 3/4 for *S. thermophilus* and Bb, respectively). **Significantly different from lipopolysaccharide (p<0.0005); n = 4.**

www.gutjnl.com
Dose dependent effect of lactic acid bacteria CM on TNF-α secretion

Figure 2A shows that in the absence of any other stimulation, *S. thermophilus* CM stimulates TNF-α secretion (487 (192) pg/ml; p<0.0003) and *B. breve* CM demonstrates a non-significant increase (150 (96) pg/ml) compared with basal secretion (49 (44) pg/ml). This basal stimulation could be due to the presence in the CM of residual Gram positive membrane components, such as peptidoglycan or LTA, known to stimulate TNF-α secretion.** Both bacteria CM exerted a dose dependent inhibitory effect on LPS induced TNF-α secretion. Compared with LPS induced TNF-α secretion (1315 (413) pg/ml), significant inhibition of TNF-α secretion by PBMC was observed in the presence of *B. breve* CM at 1/2 dilution (804 (400) pg/ml, 39% inhibition; p<0.001) and 3/4 dilution (468 (172) pg/ml, 64% inhibition; p<0.001). *S. thermophilus* CM also inhibited LPS induced TNF-α secretion with a maximal effect at 1/2 dilution (71% inhibition; p<0.001), 3/4 dilution being toxic to immune cells. The culture media used to produce bacteria CM, by themselves, did not inhibit TNF-α secretion (not shown). In THP-1 cells (fig 2B) under basal conditions, *B. breve* CM displayed a non-significant increase (323 (101) pg/ml) in TNF-α secretion compared with basal secretion (46 (34) pg/ml) whereas *S. thermophilus* CM did not stimulate TNF-α secretion (81 (52) pg/ml) in contrast with what was observed with PBMC. Again, in the presence of LPS, TNF-α secretion (2938 (501) ng/ml) was increased, and *B. breve* or *S. thermophilus* CM highly inhibited (1160 (184) and 560 (124) ng/ml, respectively; p<0.001) such secretion.

Viability studies using flow cytometry showed that *B. breve* CM did not induce cell death even at a high dose (3/4 dilution) as PBMC apoptosis was approximately 11% under control conditions and 13% in the presence of *B. breve* CM. However, incubation of *S. thermophilus* CM with PBMC led to a death rate of 20% at 1/2 dilution but of 90% at the highest concentration (3/4 dilution).

**Effect of bacteria CM on TNF-α secretion by LTA induced PBMC**

Figure 3 shows that LTA, a major compound of the Gram positive bacterial cell wall, stimulates TNF-α secretion (880 (147) pg/ml) and that both lactic acid bacteria CM inhibit LTA stimulated TNF-α secretion (383 (50) and 642 (39); p<0.0001 for *Bb* and *St* CM, respectively).

**Effect of bacteria CM on IL-10 secretion by PBMC**

IL-10 secretion by PBMC was identical in the presence or absence of LPS (not shown). Figure 4 shows that basal secretion of IL-10 (52 (27) pg/ml) was significantly increased in the presence of *B. breve* CM (3/4 dilution) (98 (24) pg/ml; p<0.0005). In the presence of *S. thermophilus* CM (1/2 dilution), IL-10 secretion was significantly decreased (13 (5) pg/ml; p<0.0006) compared with basal secretion.

**Characterisation of active bacterial metabolites**

**Pepsin-trypsin hydrolysis**

Pepsin/trypsin treated *B. breve* (462 (153) pg/ml) and *S. thermophilus* CM (394 (139) pg/ml) were found to have an inhibitory effect compared with control LPS stimulation (1185 (165) pg/ml; p<0.0001) (fig 5). Native and hydrolysed bacteria CM had the same inhibitory effect, indicating that digestive enzymes do not alter their inhibitory capacity and that active bacterial metabolites are probably not proteins.

**Selective ultrafiltration**

Figure 6 shows that filtrates containing metabolites <10 kDa still decreased TNF-α secretion (330 (46) pg/ml and 680 (96) pg/ml for *Bb* and *St*, respectively; p<0.0001) compared with LPS induced secretion (1189 (66) pg/ml). Filtrates containing metabolites <3 kDa also significantly decreased TNF-α secretion (690 (74) pg/ml and 759 (325) pg/ml for *Bb* and *St*, respectively; p<0.0001) whereas retained fractions did not, indicating that most of the active bacterial metabolites have a molecular mass lower than 3 kDa.

**Active bacterial metabolites inhibit LPS binding to THP-1 cells**

As shown in fig 7, in the presence of LBP (contained in serum AB), LPS-FITC binding to CD14 receptors expressed on mature THP-1 cells was small but significant (mean fluorescence intensity 7.0 (0.4)). There was also a small
Probiotics and inflammation 825

pretreatment at 4˚C with (contained in human serum AB (SAB)) (CD14 dependent binding). After bovine serum albumin (BSA) (CD14 independent binding). This binding determined by flow cytometry. Compared with autofluorescence, there was a small amount of binding of LPS to THP-1 cells in the presence of bovine serum albumin (BSA) (CD14 independent binding). This binding was significantly increased in the presence of LPS binding protein (contained in human serum AB (SAB)) (CD14 dependent binding). After pretreatment at 4˚C with SAB or Bb-CM in the presence of SAB, CD14 dependent LPS-FITC binding to THP-1 cells was significantly inhibited. ***Significantly different from the other conditions (p<0.0001); n = 6 separate experiments.

Active metabolites from B breve and S thermophilus decrease NFkB nuclear translocation in THP-1 cells

In this study, active metabolites of molecular mass <3 kDa were used. As shown in fig 8, LPS stimulated nuclear translocation of NFkB and the density of this band was arbitrarily taken as 100% activation. In the presence of LPS, B breve and S thermophilus CM (filtrated fraction <3 kDa) inhibited LPS induced NFkB nuclear translocation by 34% and 35%, respectively.

Active bacterial products retain their anti-TNF-α properties after intestinal transport

We tested the capacity of bacterial metabolites to cross the epithelial barrier as their anti-inflammatory effect should normally take place in the lamina propria where immune cells are located rather than in the intestinal lumen. As presented in fig 9A, basolateral compartments, potentially containing inhibitory factors after transepithelial transport of bacterial CM, were tested for their capacity to inhibit LPS induced TNF-α secretion by PBMC, under basal and inflammatory conditions. As shown in fig 9B, basolateral compartments obtained under basal conditions (epithelial control) had an inhibitory effect on TNF-α secretion (44% and 45% inhibition under basal and inflammatory conditions, respectively; p<0.0001). This suggests that epithelial cells by themselves release anti-TNF-α factors that may be distinct from TGF-β. Under basal conditions, B breve CM were still able to inhibit TNF-α secretion (p<0.0012) following intestinal transport (S thermophilus CM also inhibited secretion although this was not significant (p = 0.07)) compared with epithelial controls. After treatment of intestinal monolayers with the inflammatory cytokines TNF-α and IFN-γ, B breve and S thermophilus CM further decreased TNF-α secretion to 23% and 37% of LPS activated secretion, respectively (p<0.0001). Under inflammatory conditions, the inhibitory capacity of bacteria CM was higher than that observed under basal conditions (p<0.02). As a control of the integrity of the epithelial barrier, the electrical resistance, R, of HT29-19A monolayers was measured in Ussing chambers following treatment with TNF-α and IFN-γ for 48 hours and then incubation with bacteria CM for 24 hours in the apical compartments (fig 9C). Under basal conditions, HT29-19A monolayers had an electrical resistance R of 122 (59) Ω·cm². B breve CM did not significantly modify R (153 (44) Ω·cm²) compared with control monolayers whereas S thermophilus CM decreased R to 67 (7) Ω·cm² (p<0.002). Under inflammatory conditions (IFN-γ and TNF-α), in epithelial controls, R significantly decreased (78 (19) Ω·cm²; p<0.0001) compared with basal conditions (122 (59) Ω·cm²). This decrease was even more pronounced in the presence of bacteria CM (R = 29 (14) and 24 (16) Ω·cm², respectively, for B breve and S thermophilus CM; p<0.0001) indicating that bacterial metabolites do not display a curative effect on the inflamed epithelial barrier.

DISCUSSION

Beneficial effects have been observed with probiotic bacteria used as adjuvants in the treatment of various digestive diseases. The most convincing effect in humans has been observed in the treatment of pouchitis. However, the mechanisms operating in the improvement in inflammatory conditions associated with digestive diseases are not completely understood and are probably complex. The beneficial activity of probiotics may be exerted through the immunomodulation of gut associated lymphoid tissue. The suggestion that commensal bacteria may have a role in induction of anti-inflammatory signals, as tested in intestinal epithelial cell lines, was reported in a study showing that non-pathogenic Salmonella were capable of inhibiting the NFkB activation pathway by preventing ubiquitination of IκB and therefore the release of proinflammatory cytokines. These results suggested that commensal bacteria, and perhaps probiotic bacteria, might induce downregulation of proinflammatory
signals mediated through NFκB, a transcription factor involved in the production of many proinflammatory cytokines or chemokines.

In the present study, secretion metabolites of two lactic acid bacteria (B breve and S thermophilus) and to a lesser extent three commensal Gram positive bacteria (R gravis, B bifidum, and neonatal streptococcus) were shown to be capable, in vitro, of inhibiting LPS induced TNF-α secretion by immune cells.

The present results suggest the possibility of self-limiting properties of commensal bacteria with respect to their own proinflammatory capacities as commensal bacteria, which are part of the dominant microflora, also displayed a dose dependent anti-inflammatory effect. Therefore, the question arises as to the benefit of using probiotic bacteria when the commensal microflora has the same beneficial effects on inflammation. One of the advantages of probiotic bacteria could reside in maintaining a higher (although transient) bacterial density in the upper gastrointestinal tract, a location normally hosting very few bacteria. This “transient colonisation” may favour downregulation of inflammatory processes developing in intestinal areas which are normally not in contact with commensal microflora or in areas where the composition of the resident microflora is altered. It is possible that probiotics represent an “exogenous” microflora exerting a local beneficial effect during intestinal transit, and that continuous intake is needed to exert such an effect. By contrast, the resident microflora would exert such an effect permanently, at least in the distal part of the small intestine and colon.

B breve CM was more efficient than S thermophilus CM in exerting anti-inflammatory properties, especially following intestinal transport, with no side effects on epithelial or immune cell viability. The inhibitory capacity of B breve and S thermophilus CM may not involve the same active metabolites as some discordance has been observed in experiments designed to better understand the mechanisms of the inhibitory effect (lower IL-10 secretion by B activation, especially in the presence of LTA induced TNF-α secretion). Active metabolites seem to be non-protein molecules (<3000 Da) but their exact nature remains to be investigated. Some bacterial metabolites, particularly short chain fatty acids such as butyrate, produced by bacterial fermentation of dietary fibres, have been shown to exert inhibitory effects on NFκB activation, especially in the presence of TNF-α both, in an intestinal epithelial cell line and in macrophages. In the present study, this possibility was excluded as bacteria CM did not contain significant amounts of butyrate. Indeed, butyrate concentration was very low (15 and 20 μM for B breve and S thermophilus CM, respectively) suggesting that butyrate was not involved as active concentrations have been reported in the micromolar range. Substantial amounts of lactic acid were found (4.5 and 9 mM for B breve and S thermophilus CM, respectively) but at
Taken together, the present results indicate that both commensal Gram positive bacteria and the probiotic bacteria Bifidobacterium breve and Streptococcus thermophilus exert an anti-TNF-α effect, at least in vitro. In addition, the findings suggest that active metabolites released by probiotic bacteria during intestinal transit may cross the intestinal layer to exert anti-inflammatory effects. This would add to the suppressive tone of the intestinal microenvironment, under basal conditions, and help downregulation of inflammation under pathological conditions. Thus immunomodulation of the gut associated lymphoid tissue may explain, at least in part, the beneficial effects of probiotic bacteria as adjuvants in the treatment of digestive inflammation.

ACKNOWLEDGEMENTS
This work was partly supported by Blédina-SA and by financial assistance from the Princesse de Monaco foundation. We also acknowledge Dr Butel for her help in performing short chain fatty acids assays and Dr G Cockier for providing us with the commensal bacterial strains.

Authors’ affiliations
S Ménard, C Candalh, J C Bambou, K Terpend, N Cerf-Bensussan, M Heyman, INSERM EMI-0212, Faculté Neckier Enfants Malades, Paris, France

REFERENCES
Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport

S Ménard, C Candalh, J C Bambou, K Terpend, N Cerf-Bensussan and M Heyman

Gut 2004 53: 821-828
doi: 10.1136/gut.2003.026252

Updated information and services can be found at: http://gut.bmj.com/content/53/6/821

These include:

References
This article cites 29 articles, 12 of which you can access for free at: http://gut.bmj.com/content/53/6/821#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/